

M-M-R II Vaccine

Version Revision Date: SDS Number: Date of last issue: 10/28/2016
4.0 04/13/2017 81085-00006 Date of first issue: 03/26/2015

SECTION 1. IDENTIFICATION

Product name : M-M-R II Vaccine

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc

Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - USA 1685

Telephone : 908-740-4000

Telefax : 908-735-1496

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

|| Combustible dust

GHS label elements

Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.

Other hazards

|| Dust contact with the eyes can lead to mechanical irritation.
|| Contact with dust can cause mechanical irritation or drying of the skin.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Sucrose	57-50-1	≥ 1 - < 5
Neomycin, sulfate (salt)	1405-10-3	< 0.1

SECTION 4. FIRST AID MEASURES

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

- | | | |
|---|---|--|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention if symptoms occur. |
| In case of skin contact | : | Wash with water and soap.
Get medical attention if symptoms occur. |
| In case of eye contact | : | If in eyes, rinse well with water.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water. |
| Most important symptoms and effects, both acute and delayed | : | Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation. |
| Protection of first-aiders | : | No special precautions are necessary for first aid responders. |
| Notes to physician | : | Treat symptomatically and supportively. |

SECTION 5. FIRE-FIGHTING MEASURES

- | | | |
|---------------------------------------|---|---|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |
| Specific hazards during fire fighting | : | Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products | : | Carbon oxides
Metal oxides
Chlorine compounds
Oxides of phosphorus
Phosphorus compounds
Nitrogen oxides (NO _x) |
| Specific extinguishing methods | : | Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area. |
| Special protective equipment | : | Wear self-contained breathing apparatus for firefighting if nec- |

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

for fire-fighters

essary.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust. Handle in accordance with good industrial hygiene and safety practice. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers. Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types: Strong oxidizing agents

M-M-R II Vaccine

Version 4.0 Revision Date: 04/13/2017 SDS Number: 81085-00006 Date of last issue: 10/28/2016
 Date of first issue: 03/26/2015

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Ingredients	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Sucrose	57-50-1	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Neomycin, sulfate (salt)	1405-10-3	TWA	1 mg/m ³ (OEB 1)	Merck
	Further information: DSEN			
		Wipe limit	0.1 mg/100 cm ²	Merck

Engineering measures : Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). Dust formation may be relevant in the processing of this product. In addition to substance-specific OELs, general limitations of concentrations of particulates in the air at workplaces have to be considered in workplace risk assessment. Relevant limits include: OSHA PEL for Particulates Not Otherwise Regulated of 15 mg/m³ - total dust, 5 mg/m³ - respirable fraction; and ACGIH TWA for Particles (insoluble or poorly soluble) Not Otherwise Specified of 3 mg/m³ - respirable particles, 10 mg/m³ - inhalable particles.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Material	:	Chemical-resistant gloves
Remarks	:	For prolonged or repeated contact use protective gloves. Wash hands before breaks and at the end of workday.
Eye protection	:	Wear the following personal protective equipment: Safety goggles
Skin and body protection	:	Skin should be washed after contact.
Hygiene measures	:	Ensure that eye flushing systems and safety showers are located close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No information available.
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available

SAFETY DATA SHEET



M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Dust can form an explosive mixture in air. Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method
---------------------	---	--

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Ingredients:**Sucrose:**

Acute oral toxicity : LD50 (Rat): 29,700 mg/kg

Neomycin, sulfate (salt):

Acute oral toxicity : LD50 (Mouse): 2,880 mg/kg

LD50 (Rat): 2,750 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 633 mg/kg
Application Route: Subcutaneous

LD50 (Mouse): 116 mg/kg
Application Route: Intraperitoneal

LD50 (Mouse): 27.6 mg/kg
Application Route: Intravenous

LD50 (Mouse): 275 mg/kg
Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Ingredients:**Neomycin, sulfate (salt):**

Species: Rabbit

Result: Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Ingredients:**Neomycin, sulfate (salt):**

Species: Rabbit

Result: No eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Ingredients:**Neomycin, sulfate (salt):**

Routes of exposure: Dermal

Species: Humans

Result: positive

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

II**Germ cell mutagenicity**

Not classified based on available information.

Ingredients:**Sucrose:**

Genotoxicity in vitro	: Test Type: In vitro mammalian cell gene mutation test Result: negative
-----------------------	---

Neomycin, sulfate (salt):

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	: Test Type: In vitro mammalian cell gene mutation test Species: Chinese hamster ovary cells Result: negative
	: Test Type: Chromosomal aberration Species: Human lymphocytes Result: positive
	: Test Type: in vitro micronucleus test Result: negative
Genotoxicity in vivo	: Test Type: Cytogenetic assay Species: Mouse Cell type: Bone marrow Application Route: Intravenous injection Result: negative

Carcinogenicity

Not classified based on available information.

Ingredients:**Neomycin, sulfate (salt):**

Species: Rat
Exposure time: 2 Years
Result: negative

IARC

No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP

No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Reproductive toxicity

Not classified based on available information.

Ingredients:**Neomycin, sulfate (salt):**

Effects on fertility	:	Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity Parent: NOAEL: 25 mg/kg body weight Result: No effects on fertility and early embryonic development were detected.
Effects on fetal development	:	Test Type: Embryo-fetal development Application Route: Oral Embryo-fetal toxicity.: NOAEL: 275 mg/kg body weight Result: No adverse effects., No teratogenic effects. Test Type: Development Application Route: Subcutaneous Developmental Toxicity: LOAEL: 6 mg/kg body weight Result: positive
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Ingredients:**Neomycin, sulfate (salt):**

Target Organs: Kidney, inner ear
Assessment: May cause damage to organs through prolonged or repeated exposure.
Remarks: Based on human experience.

Repeated dose toxicity**Ingredients:****Neomycin, sulfate (salt):**

Species: Mouse
LOAEL: 30 mg/kg
Application Route: Subcutaneous
Exposure time: 14 d
Target Organs: Kidney
Species: Guinea pig
NOAEL: 50 mg/kg
LOAEL: 100 mg/kg
Application Route: Intramuscular
Exposure time: 30 - 60 Weeks

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Target Organs: ear

Species: Guinea pig

NOAEL: 10 mg/kg

Application Route: Oral

Exposure time: 90 d

Remarks: No significant adverse effects were reported

Species: Guinea pig

LOAEL: 100 mg/kg

Application Route: Subcutaneous

Exposure time: 34 d

Species: Dog

NOAEL: 100 mg/kg

Application Route: Oral

Exposure time: 6 Weeks

Remarks: No significant adverse effects were reported

Species: Dog

LOAEL: 24 mg/kg

Application Route: Intramuscular

Exposure time: 30 d

Target Organs: Kidney

Species: Rat

LOAEL: 25 mg/kg

Application Route: oral (feed)

Exposure time: 84 Weeks

Target Organs: ear

Symptoms: hearing loss

Remarks: mortality observed

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Ingredients:****Neomycin, sulfate (salt):**

Skin contact

: Symptoms: Sensitization
Remarks: May irritate skin.

Eye contact

: Remarks: May cause eye irritation.

Ingestion

: Symptoms: Nausea, Vomiting, Diarrhea, tinnitus, hearing loss,
Loss of balance

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Ingredients:****Neomycin, sulfate (salt):**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 72 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 LC50 (Americamysis): 39 mg/l Exposure time: 96 h Method: US-EPA OPPTS 850.1035
Toxicity to algae	:	EC50 (Anabaena flos-aquae (cyanobacterium)): 0.00075 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Anabaena flos-aquae (cyanobacterium)): 0.0003 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 EC50 (Pseudokirchneriella subcapitata (green algae)): 0.0099 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 0.0022 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	1,000
M-Factor (Chronic aquatic toxicity)	:	10
Toxicity to microorganisms	:	EC50 (Natural microorganism): 107.6 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 EC10 (Natural microorganism): 2.8 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Persistence and degradability**Ingredients:****Neomycin, sulfate (salt):**

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Biodegradability : Result: rapidly degradable
Biodegradation: 50 %
Exposure time: 1.2 d
Method: OECD Test Guideline 314

Bioaccumulative potential**Ingredients:****Sucrose:**

Partition coefficient: n-octanol/water : Pow: < 1

Neomycin, sulfate (salt):

Partition coefficient: n-octanol/water : log Pow: < -2

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number : UN 3077
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Neomycin, sulfate (salt))
Class : 9
Packing group : III
Labels : 9

IATA-DGR

UN/ID No. : UN 3077
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Neomycin, sulfate (salt))
Class : 9
Packing group : III
Labels : Miscellaneous

SAFETY DATA SHEET



M-M-R II Vaccine

Version 4.0 Revision Date: 04/13/2017 SDS Number: 81085-00006 Date of last issue: 10/28/2016
Date of first issue: 03/26/2015

Packing instruction (cargo aircraft) : 956

Packing instruction (passenger aircraft) : 956

IMDG-Code

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.
(Neomycin, sulfate (salt))

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

UN/ID/NA number : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.
(Neomycin, sulfate (salt))

Class : 9

Packing group : III

Labels : CLASS 9

ERG Code : 171

Marine pollutant : yes(Neomycin, sulfate (salt))

Remarks : Above applies only to containers over 119 gallons or 450 liters., Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

Ingredients	CAS-No.	Component RQ (lbs)	Calculated product RQ (lbs)
Disodium hydrogenorthophosphate	7558-79-4	5000	90909

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Fire Hazard

SAFETY DATA SHEET



M-M-R II Vaccine

Version 4.0 Revision Date: 04/13/2017 SDS Number: 81085-00006 Date of last issue: 10/28/2016
Date of first issue: 03/26/2015

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

D-Glucitol	50-70-4
Gelatins	9000-70-8
Sodium chloride	7647-14-5
Sodium phosphate, monobasic	7558-80-7
Disodium hydrogenorthophosphate	7558-79-4
Sucrose	57-50-1

California Prop. 65

WARNING: This product contains a chemical known in the State of California to cause birth defects or other reproductive harm.

Neomycin, sulfate (salt)	1405-10-3
--------------------------	-----------

California List of Hazardous Substances

Disodium hydrogenorthophosphate	7558-79-4
---------------------------------	-----------

California Permissible Exposure Limits for Chemical Contaminants

Sucrose	57-50-1
---------	---------


The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS® IV:

HEALTH	/	0
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/13/2017

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a

SAFETY DATA SHEET



M-M-R II Vaccine

Version	Revision Date:	SDS Number:	Date of last issue: 10/28/2016
4.0	04/13/2017	81085-00006	Date of first issue: 03/26/2015

guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8